Expansion into Workers' Comp Recent launches of RelieVRx for workers' compensation patients, payers, and physicians indicate a growing entry point for enterprise Health Plans and TPAs. Target opportunities include WC program adoption, clinical pathways, and payer-side reimbursement discussions to expand coverage.

Clinical Validation Advantage RelieVRx is FDA-authorized with Breakthrough Device Designation and De Novo authorization for chronic lower back pain, backed by multiple trials and over 1,200 patients. Use this to position the solution as a validated, high-trust option for chronic pain management in healthcare systems and alternative payment models.

Strategic Partnerships Past collaborations with Veterans Affairs and the VHA hospice testing demonstrate readiness for partnerships with government, veteran health networks, and integrated delivery networks. Leverage these relationships to access large, multi-site accounts and bundled care initiatives.

CMS and Coverage Framing RelieVRx has achieved a unique CMS code and coverage category, suggesting favorable reimbursement dynamics. Sales efforts can emphasize streamlined reimbursement pathways to hospitals, clinics, and health systems pursuing value-based care and reduced opioid usage.

Digital Health Scale Cloud-based, home-accessible ITx therapy aligns with telehealth workflows and remote patient monitoring. Opportunities exist to integrate with digital front doors, care management programs, and patient engagement platforms to drive adherence and scalable rollout.